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(groups III and IV).In other words, resistin was found to correlate significantly with all obesityassociated parameters. Plasma visfatin levels were significantly higher in groups II and IV being higher in group IV when compared to the control groups I and III, whereas no significant difference existed between control groups I and III. Visfatin also positively correlated with, fasting plasma insulin (r =
0
INTRODUCTION
Polycystic ovary syndrome (PCOS), is a very common endocrine disorder affecting up to 10% of women of reproductive age. It is expressed as chronic anovulation and hyperandrogenism (1,2) ,and its clinical manifestations often start at puberty (3) . Insulin resistance with compensatory hyperinsulinismia is a prominent feature of PCOS. Both lean and obese women with PCOS show reduced insulin sensitivity and hyperinsulinemia to some extent, but insulin resistance is enhanced by the interaction between obesity and the syndrome (4) . Hyperinsulinismia is thought to result in increased androgen biosynthesis (5) and decreased levels of sexhormone-binding globulin (SHBG) (6) , thus playing a major role in the pathogenesis of hyperandrogenism .In addition to reproductive morbidity, insulin resistance and the resultant hyperinsulinism put patients at risk for long -term metabolic disorders, such as impaired glucose tolerance (up to 35%) and type 2 diabetes (up to 10%) 
SUBJECTS & METHODS

RESULTS
The clinical and biochemical parameters of women with PCOS and healthy controls are summarized in table 1.There was no major difference between the two groups with respect to age, BMI and fasting plasma glucose. Compared to the controls, women with PCOS had significantly higher serum concentrations of LH (p<0.001), LH/FSH ratio (p<0.001) and free testosterone (p<0.001). Women with PCOS had significantly lower FSH levels compared to controls (p<0.001).
The plasma insulin levels were significantly higher (p<0.001) in PCOS compared to the control group. Women with PCOS had significantly higher HOMA values compared to matched controls consistent with the PCOS group being more insulin resistant than the control group.
Mean serum resistin levels was significantly higher in PCOS women (13.26±7.58ng/ml) compared to normal controls (7.95±2.17ng/ml) (p=0.003). Also, mean plasma visfatin levels was significantly higher in PCOS women (35.82±8.94ng/ml) compared to normal controls (11.88±1.84ng/ml) (p<0.0001). Values are expressed as mean ± SD. P < 0.05 was considered significant.
Clinical and biochemical parameters of all subjects based on BMI stratification are summarized in table 2. Groups III and IV had significantly higher BMI compared to groups I and II (p< 0.001). Women with PCOS (groups II and IV) had significantly lower FSH levels (p< 0.001) compared to control groups (I and III) In contrast, LH levels were significantly higher in women with PCOS (groups II and IV) compared to control groups (I and III) (p< 0.001). Also, women with PCOS with BMI > 25Kg/ m 2 had higher LH levels than women with PCOS with BMI< 25Kg/ m 2 . The same results were detected as regards the LH/FSH ratio (p< 0.001). Women with PCOS (group IV) had significantly higher free testosterone levels (p< 0.001) compared to PCOS (group II).
Blood glucose levels were significantly higher in women with BMI> 25Kg/m 2 (group III versus I; p< 0.05; group IV versus I; p< 0.001; IV versus II ; p< 0.001) whereas no significant difference was observed between women with BMI< 25Kg/m 2 of groups I and II .Compared to normal controls (groups I and III), women with PCOS with BMI > 25Kg/m 2 had significantly higher plasma insulin levels (p< 0.001and p< 0.001), respectively. Also, control group III had significantly higher plasma insulin level (p< 0.001) compared to control group I. However, insulin resistance (assessed by HOMA) was significantly higher in women with PCOS with BMI > 25Kg/m 2 compared to groups I, II and III (p< 0.001, p< 0.001 and p< 0.001), respectively.
Serum resistin levels in groups III and IV were significantly higher compared to groups I and II (p< 0.001, p< 0.001) being higher in women with PCOS with BMI > 25Kg/m 2 . Whereas no significant difference existed between women with PCOS with BMI < 25Kg/ m 2 and control women with BMI < 25Kg/ m 2 ( Fig.1) .
Plasma visfatin levels were significantly higher in women with PCOS (groups II and IV) being higher in in women with PCOS with BMI > 25Kg/m 2 when compared to the control groups (I and III). Whereas no significant difference existed between control groups (I and III) (Fig.2) . 
Fig (2): Plasma visfatin levels (ng/ml) in studied groups
Calculation of Pearson coefficient showed that in the whole study group, resistin correlated positively with BMI, LH, LH/FSH ratio, plasma insulin, fasting plasma glucose, free testosterone, HOMA and visfatin. Serum resistin levels were found to correlate negatively with FSH (table  3) 
DISCUSSION
Polycystic ovary syndrome is a heterogeneous syndrome characterized by hyperandrogenism and insulin resistance (1) . The aim of the study is to assess the relationship between both serum resistin and plasma visfatin and insulin resistance and hyperandrogenism in PCOS patients.
In In the present study, resistin levels did not differ significantly between women with BMI < 25Kg/m 2 (groups I and II). However, women with PCOS and BMI < 25Kg/ m 2 had higher levels of insulin, higher HOMA index, in other words, they were more resistant to insulin. Nevertheless, resistin levels were significantly higher in women with BMI>25 kg/m 2 (groups III and IV) compared to women with normal BMI (groups I and II), as were blood glucose and insulin levels and HOMA index.
In addition, in the current present work, resistin correlated positively with BMI, fasting plasma glucose, fasting plasma insulin and HOMA index in women with BMI>25 kg/m 2 (groups III and IV). In other words, resistin was found to correlate significantly with all obesityassociated parameters. These findings suggest that resistin is not associated with insulin resistance of PCOS that is not induced by obesity.
In the present study population the free testosterone levels were significantly higher in females with PCOS (groups II and IV) compared to controls (I and III). Pandidis et al. reported decreased levels of sexhormone-binding globulin (SHBG) in PCOS females. Nestler et al. determined that the reduced levels of SHBG were further induced by obesity (9) . That relationship explains the higher levels of free testosterone in women with PCOS and BMI > 25 kg/m 2 compared with women with PCOS and normal BMI.
Also, there was a significant positive correlation between serum resistin and testosterone in PCOS patients (groups II and IV) only. Munir et al.
(45) showed similar results. On the contrary, Pandidis and coworkers (44) found no correlation between serum resistin and testosterone. In our study, there was no correlation between circulating resistin and testosterone in control subjects and between BMI and testosterone, indicating that there may be important differences in polycystic ovaries facilitating the responsiveness of the theca cells to resistin. The current results apparently support the notion that, resistin in vitro, can increase ovarian androgen production by directly stimulating ovarian theca cells (45) . These data raise the possibility that resistin may play a role in augmenting androgen biosynthesis in women with PCOS.
Our data showed that plasma visfatin levels were higher in women with PCOS (groups II and IV This may indicate that visfatin could influence ovarian androgen secretion, however, we cannot rule out the influence of other unknown factors, which might regulate the release of both substances. Fukahara et al.
(31) reported that visfatin exerts insulin-mimetic properties through stimulation of insulin receptor. In view of the fact that hyperinsulinemia might stimulate ovarian androgen synthesis and secretion (5) and thus contribute to the pathogenesis of PCOS, it is possible that relationships observed in our study might be due to insulin-like visfatin action.
The present results showed that in the whole study group, visfatin correlated positively with resistin, while in subgroup analysis, such correlation was found only in women with PCOS (groups II and IV).
As previously mentioned women with PCOS have proportionally more visceral adipose tissue (1) and Curat et al.
(48) reported that the increased macrophage population in human visceral white adipose tissue (WAT) might be responsible for the enhanced production of chemokines as well as resistin and visfatin specially in obese subjects.
In conclusion, the results of the study showed that women with PCOS exhibit higher serum resistin and plasma visfatin levels than control subjects. The present data suggest that resistin levels correlate with insulin resistance as a consequence of obesity itself, rather than a, causative factor. We also arise the possibility that resistin may play a role in augmenting androgen biosynthesis in women with PCOS. The positive correlation between plasma visfatin levels and both insulin and HOMA possibly indicates that in certain conditions visfatin cannot exert its potential beneficial metabolic actions or its increase is a secondary event in order to prevent further development of insulin resistance. Finally, the positive correlation of visfatin with free testosterone in PCOS women could be explained by the insulin-like visfatin action that might stimulate ovarian androgen synthesis and secretion and thus contribute to the pathogenesis of PCOS.
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